Phio Pharmaceuticals Corp.
PHIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.85
KIRA · Stoqly’s AI analyst, in plain words
- Phio Pharmaceuticals Corp. lost $8.7M in fiscal 2025.
- Free cash flow was −$8.0M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$8.7M
Free cash flow
−$8.0M
Operating margin
—
Phio Pharmaceuticals Corp. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.7M
No. It lost money last year.
What Phio Pharmaceuticals Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Phio Pharmaceuticals Corp.
- CIK
- 0001533040
Phio Pharmaceuticals Corp. · PHIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | −$0.0M | $0.2M | — |
| Net interest income | — | — | −$0.0M | $0.2M | — |
| Operating margin | — | — | 135,300.0% | −3,197.8% | — |
| Net income | −$13.3M | −$11.5M | −$10.8M | −$7.2M | −$8.7M |
| Net margin | — | — | 135,325.0% | −3,095.2% | — |
| Diluted EPS | −$12.43 | −$10.10 | −$46.76 | −$9.08 | — |
| Cash | |||||
| Cash from operations | −$11.9M | −$12.1M | −$10.7M | −$7.1M | −$8.0M |
| Capital expenditure | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$11.9M | −$12.3M | −$10.8M | −$7.1M | −$8.0M |
| FCF margin | — | — | 134,425.0% | −3,079.2% | — |
| Share count change | −76.7% | 6.3% | −79.6% | 240.2% | — |
| Debt and strength | |||||
| Cash and short-term investments | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $21.9M | $10.8M | $7.7M | $4.7M | $20.1M |
| Current ratio | 8.1x | 6.4x | 5.7x | 5.7x | — |
| Returns and quality | |||||
| Return on equity | −76.0% | −70.1% | −116.6% | −114.8% | −69.9% |
| Return on tangible equity | −60.6% | −105.9% | −140.1% | −151.4% | −43.2% |
| Piotroski F-score | 5 | — | — | 2 | — |
| Altman Z'' | −6.0 | −27.5 | −45.9 | −81.5 | — |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Phio Pharmaceuticals Corp. · PHIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.85 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001533040). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.